STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Ribupatide

Also known as

HRS-9531 · HRS9531 · KAI-9531 · Kailera / Hengrui dual GLP-1/GIP · ribupatide oral · ribupatide injection

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic SubQ / oral Metabolic / GLP-1 class

Systemic dual GLP-1/GIP — weekly injection (KaiNETIC / China Phase 3) and a separate once-daily oral program.

What people say Ribupatide (HRS9531/KAI-9531) is an investigational dual GLP-1/GIP peptide in separate once-weekly injection and once-daily oral programs. Formulations and milligram scales are not interchangeable. Doses people talk about
Blinded trial diary3 mg once weekly at the four-month update

Weight loss and little nausea were reported, but unknown allocation means exposure was unconfirmed.

China injection Phase III2, 4 or 6 mg SC once weekly

567-participant, 48-week trial; 6 mg treatment-policy mean loss was 17.7% versus 1.4% placebo.

China injection Phase II8 mg SC once weekly

Separate 36-week trial; company reported 23.6% mean loss from baseline versus 1.8% placebo.

Oral Phase II10, 25 or 50 mg oral once daily

166-adult China trial over 26 weeks; oral tablet amounts are not injectable equivalents.

Global KaiNETIC programUp to 10 mg SC once weekly

Planned Phase III exposure through 76 weeks; no outcome follows from the maximum.

Descriptive trial/report amounts, not progression. Diary allocation was unknown; Phase II, Phase III, oral and injectable doses cannot be merged.

Half-life & effect duration

Half-life in the body
  • Injected · company study estimateAbout 1 week
Felt duration people report
  • Blinded trial accountLittle nausea around month 4; occasional nausea or heartburn later
  • Within-week durationNot consistently reported
Timing context & sources
How it may feel Community diary evidence is thin and blinded. One trial participant reported little nausea around four months and later occasional nausea/heartburn with weight loss; unknown allocation prevents attribution.
Cycles people discuss Formal programs study chronic once-weekly injection or once-daily oral use, not short community cycles. Global KaiNETIC extends through 76 weeks; one blinded diary spans months. Timing Injection programs use once-weekly schedules, while the oral study used once-daily tablets. Those are formulation-specific programs; their milligrams and timing cannot be merged or converted. Stacks Formal trials evaluate ribupatide as study treatment. Community discussion mainly compares it with tirzepatide, enicepatide or mazdutide; comparison is not evidence for combined use. Watch for Unapproved in the US.
Related
TirzepatideEnicepatideMazdutideSemaglutideRetatrutide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A company-reported Phase Ib injection study estimated ribupatide terminal half-life at about one week.

Adults with type 2 diabetes received weekly SC HRS9531 across 0.3–4.5 mg for four weeks; the report says terminal half-life about one week and single-dose median Tmax 72.0–94.8 hours.

Conference/company summary, approximate value, short exposure, diabetes population and injectable formulation; not transferable to oral tablets.

  • Hengrui — HRS9531 injection Phase Ib in type 2 diabetes (opens in a new tab)63 participants received at least one treatment; 0.3/1.5/up-to-4.5 mg SC weekly for four weeks. Company conference report says terminal half-life about one week and single-dose median Tmax 72.0–94.8 h.Chinese-language company conference summary, not a full peer-reviewed PK table; approximate and formulation-specific.

Felt duration people report

No ribupatide-specific per-dose felt-duration window was established in the inspected community evidence.

A blinded participant described little nausea around four months and occasional nausea/heartburn later, but unknown assignment means exposure was unconfirmed and no within-week clock was reported.

One anonymous blinded account without verified assignment, records or per-dose timing; class expectations cannot substitute.

Other context in this card

What people say 4

  • Class dual appetite: Import tirz food-noise talk until there is a real English logbook. forum
  • China injection trials: Phase II reported 23.6% mean loss from baseline at 8 mg by week 36 versus 1.8% placebo. Separate Phase III reported 17.7% at 6 mg by week 48 versus 1.4% placebo under the treatment-policy estimand; the hypothetical estimand was 19.2%. trial
  • Oral Phase 2: Up to ~12.1% at 26 weeks, no plateau in the press line. trial
  • KaiNETIC: Three global Phase 3 weekly-injection trials, data talked as 2028. trial

Doses people talk about 5

  • Do not put 25 mg oral on a 10 mg pen. forum
  • US high-dose 2b: Weekly up to 20 mg, 48 weeks, BMI≥35, readout talked 2027. trial
  • China injectable quotes: 6 mg and 8 mg weekly in the % headlines. trial
  • Injectable Phase 3 (KaiNETIC talk): Weekly SC up to 10 mg over ~76 weeks. trial
  • Oral Phase II: 10, 25 or 50 mg once daily for 26 weeks; company topline reported 6.9%, 12.1% and 12.1% mean loss from baseline under the efficacy estimand. Oral and injectable milligrams are not interchangeable. trial

How it may feel 3

  • Blinded participant account: A U.S. trial participant reported reaching 3 mg weekly around four months, losing 23 lb with little nausea, and later 37 lb since April with occasional nausea and heartburn. Allocation was blinded, so this cannot identify ribupatide as the cause. anecdote
  • Oral vs pin: Two feel curves. Oral 26-week 12% will not feel like an 8 mg China pin. forum
  • If a Discord vial says HRS-9531: Assume identity risk first, feel-curve second. forum

Cycles people discuss 2

  • Weekly injection, chronic. trial
  • Oral daily, chronic, China-first. trial

Timing 2

  • Injectable designed weekly — long-acting dual peptide. Public English t½ tables are thinner than tirz; do not invent hours. forum
  • Oral is a different PK problem. trial

More on what it is 5

  • Feel-log honesty: US diary layer is thin. Most “how it feels” is class dual + China-trial tables. forum
  • What it is: Hengrui’s dual agonist. Injectable = HRS-9531 / KAI-9531 (Kailera’s global name ribupatide). There is also an oral ribupatide. Not tirz. Not approved in the US. trial
  • Why people talk about it: Separate China injection trials reported 23.6% mean loss from baseline at 8 mg by week 36 in Phase II and 17.7% at 6 mg by week 48 in Phase III under the treatment-policy estimand. These are company-reported trial results, not one combined Phase III figure. trial
  • How it works: Dual incretin — same cartoon as Mounjaro. trial
  • Two products: Weekly pin (global Phase 3 up to 10 mg, high-dose 2b up to 20 mg) vs daily oral (China Phase 3 bound; ~12% at 26 weeks in an oral Phase 2). Do not mash the mg. trial

Stacks 2

  • Mental stack: vs tirz / enicepatide / mazdutide. forum
  • Solo in the trials. trial

Storage notes 1

  • No STUD mix chart. “HRS-9531” research vials are not KaiNETIC drug. forum

Watch for 5

  • Geography: China % may not copy onto a US body — that is the KaiNETIC question. forum
  • Two modalities, two mg languages. forum
  • Unapproved in the US. forum
  • Gray dual vials. forum
  • Class GI. trial

Updated: 2026-08-17

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →